All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
5 warning events since 2017; the latest 2025-12-16.
From the record
Intelligent Bio Solutions Inc.'s filings since 2017 show 5 warning events of 2 kinds: a notice about its exchange listing (8-K item 3.01, 4 times, the latest 2025-12-16); an auditor change (8-K item 4.01, the latest 2023-07-03) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+16.3% a year over 6 filed years; profitable in 0 of 6.
From the record
Intelligent Bio Solutions Inc.'s 6 filed years say what it did: revenue went from $2 million in fiscal 2021 to $4 million in fiscal 2026, up 16.3% a year; it rose in 3 of 5 years; the deepest fall was 78% from fiscal 2021 to fiscal 2022; net income was positive in 0 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 0.6/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Intelligent Bio Solutions Inc.'s shareholder treatment is put at 0.6 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 5% of 120 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -226%: lost 226¢ per shareholder dollar. Leverage 54%: owes 54¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2026-06-30, Intelligent Bio Solutions Inc. lost about 226 cents for every dollar of shareholders' money, and gross profitability: its products earned about 17 cents per dollar of everything the company owns. Leverage: it owed about 54 cents per dollar of assets, and net share issuance: its share count grew 179.3% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 40% of 109 in its family; net margin -294.9%.
From the record
Intelligent Bio Solutions Inc.'s standing among 109 graded names in its industry family: revenue of $4 million in fiscal 2026 ranks in the bottom 16% by size; a net margin of -294.9% ranks in the bottom 18%; revenue growth of 49.7% a year over the last 3 filed years ranks in the top 14% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 37% of 91 in its family for leadership; chief executive since 2023.
From the record
Intelligent Bio Solutions Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Simeonidis, Harry (Chief Executive Officer, as filed), filing under that title since 2023-09-05, 3.2 years (bottom 41% of its family); the 6 officers and directors filing in the last fifteen months have been on the record a median of 5.9 years (top 44%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 6 people in charge now (bottom 14%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 39% of 104 in its family for room to expand.
From the record
Intelligent Bio Solutions Inc.'s room to grow, from the newest filed statements (fiscal 2026): cash of $4 million against no long-term debt tagged leaves 33.4% of its assets as net cash, top 26% of its family; cash from operations less capital spending is -285.9% of revenue (bottom 13%); a gross margin of 48.6% (bottom 30%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 33% of 105 in its family for growth drivers.
From the record
Intelligent Bio Solutions Inc.'s growth drivers, from the filed years to fiscal 2026: revenue grew 49.7% a year over the last three filed years against 16.3% over all 6, speeding up (top 6% of its family); the newest year grew 38.1% (top 16%); capital spending grew -24.7% a year (bottom 22%) (its annual reports). Intelligent Bio Solutions Inc. reported 3 product lines in fiscal 2026: Sales of Goods Cartidges at $2 million (59%), Sales of Goods Readers at $902 thousand (21%), Other Sales Accessories at $827 thousand (20%); 3 of 3 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 50% of 88 in its family for expectations against reality.
From the record
Intelligent Bio Solutions Inc.'s newest year against its own record: revenue of $4 million in fiscal 2026 came in 11.4% below the $5 million its prior three years' pace pointed to (bottom 30% of its family); net income of $12 million against a prior three-year average of $10 million (bottom 30%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 9%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made